Quantum Biopharma LTD

20-F13D13G

Schedule 13D - Activist Investments

NASDAQ
Malone Wealth Ventures LLC and its President and CEO, Kevin Malone, have disclosed a beneficial ownership of 17.8% of Quantum Biopharma Ltd.'s common stock, with Mr. Malone also serving as an Advisor to the Board.
NASDAQ
Malone Wealth Ventures LLC and its President Kevin Malone have increased their beneficial ownership in Quantum Biopharma Ltd. to 17% through open market purchases and compensation grants, indicating potential influence over the issuer's strategic direction.
NASDAQ
Malone Wealth Ventures LLC has filed an amended Schedule 13D, revealing a beneficial ownership of 14.8% of Quantum Biopharma Ltd.'s common stock.
NASDAQ
Malone Wealth Ventures LLC has disclosed a 14.6% beneficial ownership stake in Quantum Biopharma Ltd., acquired for investment purposes, with its CEO also serving as an advisor to the issuer's board.
Capital raise

Schedule 13G - Passive Investments

See all →
NASDAQ
AdvisorShares Trust has reported beneficial ownership of 203,564 Class B Subordinate Voting Shares in Quantum Biopharma Ltd., representing 5.33% of the class.
NASDAQ
Malone Wealth Ventures LLC has reported a 9.8% beneficial ownership stake in Quantum Biopharma Ltd., holding 375,752 shares of common stock.
NASDAQ
Malone Wealth Ventures LLC has reported a 27.4% beneficial ownership stake in Quantum Biopharma Ltd.'s common stock.
NASDAQ
Malone Wealth Ventures LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 21.8% of Quantum Biopharma Ltd.'s common stock.
NASDAQ
Malone Wealth Ventures LLC has disclosed a beneficial ownership of 19.4% of Quantum Biopharma Ltd.'s common stock, holding 735,148 shares as a passive investment.
NASDAQ
Malone Wealth Ventures LLC has disclosed a 19.4% beneficial ownership stake in Quantum Biopharma Ltd., holding 735,148 shares of common stock.